Abstract:Identifying the alert groups of mechanism-based inactivators of human cytochrome P450s (hCYPs) is very helpful for early prediction of drug toxicity and for rational drug design to avoid idiosyncratic toxicity. Here, we report that a natural compound bufalin (BF) could time-dependently inactivate hCYP3A via complex CYP-catalyzed cascade oxidative metabolism. Metabolite profiling and time-dependent inhibition assays showed that 3-keto-bufalin (3-KBF), a unique nonpolar oxidative metabolite of BF, was the key substance responsible for hCYP3A inactivation. Further investigations demonstrated that 3-KBF was further metabolized by hCYPs to generate two mono-hydroxylated metabolites, which could be readily dehydrated and then covalently bound on glutathione or hCYP3A4. Collectively, this study uncovers unique CYP-catalyzed cascade oxidative pathways of BF in which two reactive intermediates bearing a Michael acceptor are finally formed as hCYP3A inactivators. These findings expand the current knowledge of CYP inactivators and suggest that some steroids bearing the 3-keto group may trigger time-dependent CYP3A inactivation.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01875.Inhibitory effects of compounds from Chinese medicine on hCYP3A; analytical conditions for quantification of the internal standard and the metabolite of midazolam; inhibitory effects of BF, 5-HBF, and 3-KBF; chemical structures of BF and its oxidative metabolites; effects of various trapping or protecting agents on the inactivation of hCYP3A by 3-KBF; time-dependent inhibition kinetics of BF and 3-KBF in rhCYP3A4; determination of the partition ratio for hCYP3A4 inactivation; mass spectra of product ions of 3-KBF; formation of the oxidative metabolites of 3-KBF in recombinant P450 enzymes; mass spectrometric characterization of the Michael receptor; MS/MS spectrum for the modified peptide from hCYP3A4; possible covalent binding poses of the reactive metabolites of 3-KBF; 2D representation of the key interactions; mass spectrometric characterization of the GSH adducts; HPLC-UV profiles of BF and 3-KBF; C-NMR and H-NMR spectra of 3-KBF, 3-KRB, and 3-KCB (PDF)This article has not yet been cited by other publications.

Bufalin Inhibits CYP3A4 Activity in Vitro and in Vivo

Bufalin Inhibits Htert Expression and Colorectal Cancer Cell Growth by Targeting CPSF4

Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A

Bufalin Inhibits Gefitinib Resistant NCI-H460 Human Lung Cancer Cell Migration and Invasion in Vitro.

Bufalin Suppresses Hepatocellular Carcinoma Invasion and Metastasis by Targeting HIF-1α Via the PI3K/AKT/mTOR Pathway.

Bufalin Inhibits NCI-H460 Human Lung Cancer Cell Metastasis in Vitro by Inhibiting MAPKs, MMPs, and NF-κB Pathways.

Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo.

Inhibition Effect of Bufalin on Invasion and Metastasis of Gastric Cancer Cells

Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice

HPLC Determination of Midazolam in Rat Plasma and Applied to Investigation the Drug Interaction

Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways

Bufalin attenuates the proliferation of breast cancer MCF-7 cells in vitro and in vivo by inhibiting the PI 3 K / Akt pathway

The Effect of Clopidogrel on Pharmacokinetics of Ivabradine and Its Metabolite in Rats

Bufalin Induces Apoptosis of MDA-MB-231 Cell Through Activation of JNK/p53 Pathway

Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer

Bufalin-Loaded PEGylated Liposomes: Antitumor Efficacy, Acute Toxicity, and Tissue Distribution

Bufalin Increases Sensitivity to Akt/Mtor-Induced Autophagic Cell Death in Sk-Hep-1 Human Hepatocellular Carcinoma Cells

Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1

Bufalin Inhibits Migration and Invasion in Human Hepatocellular Carcinoma SK-Hep1 Cells Through the Inhibitions of NF-kB and Matrix Metalloproteinase-2/-9-signaling Pathways.

Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma

Bufalin Enhances Anti-Angiogenic Effect of Sorafenib Via AKT/VEGF Signaling.